Clinical studies on entecavir therapy for the treatment of chronic hepatitis B

YANG Yuan-su; LI Li; HUANG Xia-han

doi:10.3969/j.issn.1007-8134.2017.01.011

Abstract：Objective To investigate the efficacy and safety of entecavir in treatment of chronic hepatitis B.Methods Seventy-seven chronic hepatitis B patients were assigned into two groups (test group and control group) randomly. The test group received oral entecavir treatment, while the control group received lamivudine treatment. The total course of treatment was 48 weeks. The changes of liver function, HBsAg, HBeAg, HBV DNA and other indexes were observed before and after treatment in 12 weeks, 24 weeks and 48 weeks.Results After 48 weeks′ treatment, the ALT recovery rate of the test group and the control group were 66.7% and 63.2%, respectively. There was no statistically significant difference between the 2 groups. The HBeAg negative conversion rate and serological conversion rate of the test group were 30.8% and 25.6%, respectively, which were higher than those of the control group (10.5% and 7.9%, respectively,P<0.05). The HBV DNA negative conversion rate of the test group was 71.8%, higher than that of the control group of 44.7%. The HBsAg negative rate and serological conversion rate in the test group were 5.1% and 2.6%, while 2.6% and 0 in the control group. There was no statistically significant difference between the 2 groups. No serious adverse reactions occurred in all patients. Conclusions Entecavir has significant curative effect for chronic hepatitis B, the effect is superior to lamivudine, and has no serious adverse reactions.